FSD Pharma Receives Institutional Review Board Approval for Unbuzzd™ Study

Tuesday, 4 June 2024, 09:00
An Institutional Review Board has approved FSD Pharma to conduct a study on Unbuzzd™ in treating Acute Alcohol Intoxication. This approval signifies a major step for FSD Pharma towards understanding the safety and efficacy of Unbuzzd™ in such conditions. The study holds the potential to provide valuable insights into the medical applications of Unbuzzd™ in managing acute alcohol intoxication.
https://store.livarava.com/a31809e1-226a-11ef-a3ff-9d5fa15a64d8.jpg
FSD Pharma Receives Institutional Review Board Approval for Unbuzzd™ Study

FSD Pharma Receives Institutional Review Board Approval for Study

An Institutional Review Board has granted FSD Pharma approval to study the safety and efficacy of Unbuzzd™ in Acute Alcohol Intoxication. This milestone marks a significant advancement in the research on Unbuzzd™ and its potential medical benefits.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe